

CLC 2010
*Remembering
Our History*



Facing Our Future



MAY 24, 25, & 26, 2010

*Crowne Plaza Riverfront
Saint Paul, Minnesota*

ver050910

CLC 2010
Table of Contents

<i>Topic</i>	<i>Page</i>
<i>Welcome.....</i>	<i>3</i>
<i>Crowne Plaza Riverfront Hotel.....</i>	<i>4</i>
<i>New and Again in 2010.....</i>	<i>5</i>
<i>Registration Information.....</i>	<i>7</i>
<i>Accommodations.....</i>	<i>8</i>
<i>Event Parking.....</i>	<i>8</i>
<i>Sponsoring Organizations.....</i>	<i>9</i>
<i>Silent Auction.....</i>	<i>13</i>
<i>Program Descriptions.....</i>	<i>14</i>
<i>Committee Members.....</i>	<i>55</i>

CLC 2010

Welcome

The CLC 2010 Planning Committee, consisting entirely of volunteers from the sponsoring organizations, has worked diligently to provide a program covering a broad range of topics designed to enhance your professional development as well as your personal growth. We sincerely hope your experience will be pleasurable and rewarding.

Please feel free to contact any committee member(s) to assist in making your experience exceptional.

Conference Goals

Promote professional standards in clinical laboratory practice, research, and education.

Promote mutual understanding, cooperation and networking between clinical laboratory science professionals in the interest of public health.

Provide valuable continuing education opportunities for clinical laboratory professionals.

Remembering Our History, Facing the Future

"We must welcome the future, remembering that soon it will be the past; and we must respect the past, remembering that it was once all that was humanly possible"

George Santayana

CLC 2010

Clinical Laboratory Collaborative 2010


May 24, 25, & 26, 2010
Monday, Tuesday, and Wednesday

Crowne Plaza Riverfront Hotel

11 East Kellogg Boulevard

Saint Paul, MN 55101

www.cpstpaul.com



Getting to St. Paul and the Crowne Plaza

The Crowne Plaza Hotel is on the St. Paul Riverfront at the intersection of Kellogg Blvd. and Wabasha St.

From airport: Go east on Highway 5 leaving the airport. Follow Highway 5 to Downtown St. Paul. (Highway 5 turns into W. 7th Street.) Turn right onto Kellogg Blvd. Follow Kellogg Blvd. to Wabasha. Turn left onto Wabasha to access hotel parking lot.

CLC 2010

New this Year!

Certification Maintenance Program A number of sessions (#'s 4, 12, 20, 26, 28, 35, & 43) are designed to help the Generalist meet the ASCP Certification Maintenance Program requirements. Also check out # 24 The Changing World of Certification.

Again in 2010!

Online CEU documentation Registrants will be able to use an online resource to verify PACE credits for attendance at this conference. Instructions will be in the registration packet.

Extended Exhibit hours! This year the exhibits will also be open on Wednesday morning, as well as Monday and Tuesday. Please visit the exhibits during the conference and thank the vendors for their participation in making this conference fun and rewarding. Your registration packet contains a complete list of those vendors and organizations that have contributed so generously of their time and resources.

No handouts will be provided for any sessions at the meeting. If you would like a handout, please visit the ASCLS website (www.asclsmn.org) after May 10th to print one for yourself.

CLC 2010

Lab Futures Don't miss the Lab Futures sessions scheduled throughout our conference. This is an interactive forum for the vendors and participants that will take place in the Exhibit Hall. The Exhibit Hall will be open only to Lab Futures participants during these designated times. Vendor representatives will meet with small groups for mini-sessions in four categories: 1) Point-of-Care testing, 2) Chemistry, 3) Computer/Software, and 4) Hematology/Coagulation. The sessions are listed in the program as LF- 1, 2, 3, or 4.

How Does Lab Futures Work?

- ◆ You must sign up for the category of your choice on the registration form. A maximum of 25-30 participants are divided among the participating vendors within each category and subgroups of 4 - 5 participants will rotate through each of the vendor exhibits in the hour allotted. **One PACE credit is given for each full session.** Register early. It is first come, first served.
- ◆ Lab Futures provides an opportunity for the participant to compare and evaluate multiple laboratory technologies. It can help new laboratorians as well as lab staff looking to purchase instrumentation or supplies, or just interested participants who want to see what's new. Products may include instruments, reagents, and supplies.
- ◆ Lab Futures sessions are scheduled throughout the conference at the same time as the other breakout sessions in the Collaborative Program. Lab Futures participants can take advantage of the undivided attention of the presenter, unlike the times when the Exhibit Hall is open to all registrants of the conference.

CLC 2010

Register one of three ways:

1. Online (www.asclsmn.org) after April 5th, 2010, using credit card for payment.
2. Print and mail registration form and fee (check made payable to ASCLS-MN) by May 17th to:
Tom Massmann
1911 Bielenberg Drive
Woodbury, MN 55125
DO NOT MAIL AFTER MAY 17th
3. Fax registration form, Attn: Tom Massmann, at 612-262-5965, from May 17 to May 21. Bring check to conference, payable to ASCLS-MN.

No rain checks or refunds will be issued for non-attendance. Sessions are approved for PACE credit. Nametags will be issued to registrants and must be worn for admission to all sessions and special functions.

For questions contact:

Meeting Co-Chair : Jillene Collins
jillenecollins@earthlink.net

Meeting Co-Chair : Carrie Bowler
bowler.carrie@mayo.edu

Meeting Co-Chair : Valerie Arends
varends1@fairview.org

CLC 2010

Accommodations

Crown Plaza Riverfront Hotel

www.cpstpaul.com

- For Hotel Room Reservations, call (651)292-1900 or (866)422-3185.
- The event guaranteed room rate is \$119.00.
- Participants must say they are with the Clinical Laboratory Collaborative.

Room amenities include:

coffee maker, iron/board, hair dryer, indoor pool/whirlpool/sauna and complimentary high speed internet.

Parking

CLC 2010 voucher parking offered at the Crowne Plaza and Capital City Plaza Parking Ramps

Crowne Plaza \$7/day \$14/overnight

Vehicle height clearance - 5 feet 9 inches

Capital City Plaza \$7/day \$17/overnight

Vehicle height clearance - 7 feet 0 inches

Additional Downtown Saint Paul Parking information can be found at www.smart-trips.org and at the ASCLS-MN website, asclsmn.org

CLC 2010

Sponsoring Organizations

American Society for Clinical Laboratory Science – Minnesota (ASCLS-MN)

Founded in 1933, ASCLS is made up of and governed by practitioners in clinical laboratory science. ASCLS-MN's mission is to promote the profession of clinical laboratory science in Minnesota and provide beneficial services to those who practice it. Besides serving on the board of directors, committees or scientific assemblies for ASCLS-MN, members may also choose to work with ASCLS national committees. ASCLS publishes a bimonthly journal, *Clinical Laboratory Science*, along with a monthly national newsletter, *ASCLS Today*. ASCLS-MN publishes a quarterly newsletter, *e-LABorate*. All laboratorians are invited to be members of ASCLS e.g. clinical laboratory scientists, clinical laboratory technicians, histotechnologists, histotechnicians, generalist, specialists, managers/supervisors, phlebotomists and others. Please join us at the ASCLS-MN Business Meeting on Monday afternoon to learn more about ASCLS and ASCLS-MN.

www.asclsmn.org

American Association of Clinical Chemistry (AACC)

With nearly 10,000 members, AACC is the largest international society of research oriented clinical laboratory professionals, physicians, research scientists and others in the field of clinical laboratory medicine. Founded in 1948, the society is headquartered in Washington, DC. AACC members come from a variety of employment settings: hospital labs (50%), industry (26%) and independent labs (24%). 30% of the membership is international. 23 local area sections and 13 specialty divisions focus on laboratory medicine subspecialties such as Point of Care, Pediatric, Maternal, Fetal, and Molecular Diagnostics, to name a few. AACC's annual meeting and exposition is often held jointly with ASCLS and is the largest in the field of laboratory medicine attracting nearly 20,000 participants and 600 exhibitors. AACC sponsors dozens of other scientific meetings each year such as the Oakridge Conference. AACC is a major publisher of books and five

CLC 2010

periodicals on clinical laboratory science. *Clinical Chemistry* is an international peer reviewed journal and is the most cited journal in the field. *Clinical Laboratory News* offers breaking news stories with feature articles and viewpoints from leading clinical laboratory scientists. *Clinical Laboratory Strategies* addresses the essentials of laboratory management and mastering change in laboratory practice. In addition to the AACC member website, Lab Tests Online (www.labtestsonline.org) has won several awards and hosts more than 700,000 visitors per month. *All attendees are welcome to sign up for the AACC Luncheon on Monday at 11:45 AM.*

www.aacc.org

American Medical Technologists (AMT/MSSAMT)

The American Medical Technologists (AMT) is a nonprofit certification agency and professional association representing over 41,000 individuals in allied health care. Established in 1939, AMT has been providing allied health professionals with professional certification services and membership programs to enhance their professional and personal growth.

Members include Medical Technologists, Medical Laboratory Technicians, Medical Assistants, Medical Administrative Specialists, Dental Assistants, Office Laboratory Technicians, Phlebotomy Technicians, Laboratory Consultants, and Allied Health Instructors. In order to become an AMT member, you need to be certified by meeting educational, professional experience and examination requirements. Once certified by AMT, members receive many valuable benefits that include educational and professional programs, career assistance, information services, networking opportunities, and many other benefits. *All attendees are welcome to sign up for the AMT Business Meeting Lunch on Tuesday at 11:45.*

www.amt1.com

American Society for Clinical Pathology (ASCP)

Founded in 1922, and with membership of more than 140,000 pathologists and laboratory professionals worldwide, the American Society for Clinical Pathology (ASCP) is the largest non-profit medical society organized for educational, scientific and charitable purposes. It serves as a principal resource for continuing education in pathology and laboratory medicine and the certification of laboratory

CLC 2010

personnel. Since 1928 the ASCP Board of Registry has certified over 400,000 laboratory professionals. Through the efforts and expertise of its volunteer faculty and leadership, each year ACSP develops more than 500 comprehensive educational programs. Members receive many benefits including ASCP's award winning monthly journals and newsletters, plus outstanding programs and networking opportunities at ASCP workshops, seminars, and regional and annual meetings. *Meet your state and regional representatives at the ASCP Luncheon on Monday.*

www.ascp.org

Association of Genetic Technologists (AGT)

The Association of Genetic Technologists. (AGT), founded in 1975, is a non-profit professional organization established to promote cooperation and exchange of information among those engaged in classical cytogenetics, molecular and biochemical genetics, and to stimulate interest in genetics as a career. Over 1,200 technologists, supervisors, and lab directors that are members of AGT comprise a network of dedicated professionals who share a common bond-an interest in genetics. AGT's annual meeting provides opportunities to develop professional contacts in the ever-expanding area of clinical and research genetics. Our publications keep members and subscribers abreast of the latest developments in the field. AGT's continuing educational opportunities assist those with professional certifications to maintain their professional credentials. In addition, various awards and volunteer opportunities allow technologists to be recognized for their contribution to the profession.

www.agt-info.org

Clinical Laboratory Management Association (CLMA)

CLMA is an international organization whose membership is responsible for laboratories and clinical services in hospitals, healthcare networks, group practices and independent settings. The Minnesota Chapter of CLMA is a professional organization dedicated to excellence in clinical services: to enhancing professional, managerial and leadership skills, to promoting efficient, productive and high quality operations, and to advocating on behalf of quality patient care and chapter membership. The Minnesota Chapter provides education, regulatory information and networking

CLC 2010

opportunities. CLMA provides e-mails with the latest regulatory updates and industry trends as well as newsletters and journals to its members. This organization is an invaluable asset for current and future laboratory leaders. *Anyone is welcome to sign up for the CLMA Business Meeting Lunch on Tuesday.*

www.mnclma.com

Minnesota Association of Blood Banks (MABB)

The Minnesota Association of Blood Banks, founded in 1955, is comprised of individuals and institutions interested in blood banking and transfusion medicine. It was formed to “encourage, promote and render a high standard of service to all communities, hospitals and those who need or will need blood and its components. We foster cooperation between agencies and individuals interested in blood banking.” Educational opportunities are available in the Newsletter and at the annual educational conference held in the fall.

Membership consists of all levels of laboratory professionals, nurses and physicians with a current membership of 99 individuals and 26 institutions. A board of directors, elected at the annual fall meeting, governs MnABB. MnABB welcomes new members and encourages you to pick up a newsletter at our information booth.

www.aabb.org

Minnesota Interlaboratory Microbiology Association (MIMA)

The Minnesota Interlaboratory Microbiology Association (MIMA) was founded in 1976 to provide a forum for the exchange of scientific knowledge and the discussion and evaluation of standard methodology, products and new developments in clinical microbiology. The association is made up of over five hundred people from across the state working in or interested in clinical microbiology. Our educational dinner meetings, held three times a year, provide a forum for invited speakers to discuss topics pertinent to the field of clinical microbiology and also afford an opportunity for the members to exchange information and ideas.

CLC 2010

10th Annual Silent Auction



**All proceeds go to the Children's Miracle Network
(Specifically Gillette Children's Specialty Healthcare)**

**Lots of wonderful items will be on display and open for
bidding during the Monday and Tuesday exhibit hours.
Bidding will close at 4:45 pm Tuesday, May 25, 2010.
Winning bidders will be announced at 5:00 pm.**

**We look forward to your participation in supporting
children's healthcare in Minnesota.
For additional information contact
Pat Powers at pat.pow01@gmail.com**



Sponsored by: ASCLS-MN

Monday, May 24th
Program Information

Monday, May 24th

7:00 AM – 8:00 AM

Registration and Continental Breakfast

8:00 AM– 9:15 AM

Keynote Presentation

*Searching for the Face of the
Laboratory*

Advanced – 1.0 C.E.U.

presented by:

Mary Ann McLane, PhD, MLS
President, ASCLS
Department of Medical
Technology,
University of Delaware



Despite the critical contribution of lab data to diagnosis and treatment decisions, the vast majority of the general public is unaware of the FACE of the clinical laboratory. This seminar will probe whose responsibility that is and how the situation can be resolved once and for all.

Monday, May 24th

Objectives:

1. Compare and contrast the factors which mitigate against the general public connecting lab test results to those who provide those results.
2. Critique the efforts of individuals and professional societies in “providing the face” of the clinical laboratory to the general public, healthcare colleagues, and legislators.
3. Outline a personal action plan to provide the face of the clinical laboratory in at least three local activities.

9:30 AM – 10:30 AM

#1 Molecular Therapies for Hematologic Malignancies

Intermediate – 1.0 C.E.U.

Sponsored by Mayo Clinic College of Medicine

William Hartman, MD, PhD

Senior Associate Consultant, Staff Anesthesiologist

Mayo Clinic College of Medicine

Cancer is still a difficult diagnosis for any person to receive. As much as people are scared of the cancer, many times they are equally frightened by the therapy for their affliction. Newer therapies are being developed to better target particular cancers so that they become more individualized and tolerable. The goals of these therapies are to maximize effectiveness and minimize side effects. In doing so, we hope to improve outcomes by decreasing adverse drug reactions and improving overall patient compliance.

Objectives:

1. Describe an example of drug discovery.
2. Discuss current hematologic cancer therapies.
3. Describe the role genomics plays in drug therapy effectiveness.

Monday, May 24th

#2 Failure Mode and Effects Analysis

Intermediate – 1.0 C.E.U.

Sponsored by Mayo Clinic

Angela Leuenberger, Systems Engineer
Mayo Clinic

This course will focus on learning when to use an FMEA and how to complete an FMEA form. We will do an example to demonstrate the form.

Objectives:

1. Explain what a Failure Mode and Effects Analysis (FMEA) is and why it's useful.
2. Recognize the basic parts to an FMEA form.
3. Understand process of completing an FMEA.

#3 Stem Cells and Their Impact on Medicine

Basic – 1.0 C.E.U.

Sponsored by



Mark S. Ellinger, J.D., Ph.D., Senior Principal
Fish and Richardson, P.C.

Dr. Ellinger will provide a background on the science of stem cells, some of the legal and ethical issues surrounding stem cells, and the potential of stem cells to revolutionize medicine.

Objectives:

1. Describe how stem cells are obtained.
2. Distinguish between embryonic and adult stem cells.
3. List 3 medical uses for stem cells.

Monday, May 24th

#4 Basic Chemistry Lab Values – Giving Meaning to the Numbers

Basic – 1.0 C.E.U

Janean Thielman, MLS Technical Consultant
HealthEast Medical Laboratory

The Clinical Chemistry Laboratory plays a critical role in helping determine the diagnosis, therapy and prognosis of disease by testing serum, plasma, urine and other body fluids for chemical components. This presentation will provide a review of the basic chemical components analyzed in the Clinical Chemistry Laboratory and how increases or decreases in these components can indicate renal function, liver function, cardiac function and much more.

Objectives:

1. List the analytes included in common Chemistry Profiles.
2. List the reference ranges and critical values for these analytes.
3. Correlate abnormal values of Chemistry analytes with health status and disease states.

10:45 AM– 11:45 AM

#5 The Dark Side of Complementary and Alternative Medicines

Intermediate - 1.0 C.E.U.

Catherine Hammett-Stabler, Ph.D., DABCC, FACB
Professor, Department of Pathology and Laboratory
Medicine, University of North Carolina, Chapel Hill, NC
President American Association of Clinical Chemistry

Approximately half of the American Population continues to embrace complementary and alternative medical (CAM) therapies and spends

Monday, May 24th

in excess of \$30 billion annually for these types of treatments. In addition, many immigrants bring traditional medicines for personal use. This session will review the most commonly used products in terms of toxicity and impact on laboratory tests.

Objectives:

1. Describe practices considered to be CAM therapies, the regulations governing these practices, and their impact on healthcare.
2. Recognize potential analytical interference from CAMs.
3. Recognize CAMs known to exhibit pharmacological effects.
4. Describe and recognize adverse reactions and toxicity related to CAM use.

#6 Pre-Analytical Variables

Advanced – 1.0 C.E.U.

Mary Ann McLane, PhD, MLS
Professor, Department of Medical Technology,
University of Delaware

The first step to correcting a problem is to identify the variables involved and then to address each one individually. Pre-analytical variables are a leading cause for misdiagnosis and thus incorrect patient treatment. This seminar will summarize the sources of pre-analytical variability in sample collection and handling, and challenge the participants with “What is wrong with this picture” actual clinical scenarios.

Objectives:

1. Compare and contrast the sources of pre-analytical variability in sample collection and handling.
2. Correlate the sources of pre-analytical error with the six patient safety aims from the Institute of Medicine.
3. Analyze actual clinical scenarios involving laboratory data and pre-analytical errors.

Monday, May 24th

#7 Levels of Practice for Laboratory Professionals

Basic - 1.0 C.E.U

Deb Rodahl, MBA, MLS, System Director for Laboratory Services, HealthEast Care System

This session will cover the process that was utilized to develop a model for laboratory professional levels of practice. This will include why and how the model was developed, how it benefits the profession, and how it can be used in practice for curriculum development or career ladders. This session will also cover the work developed around all the factors to consider before the model can be implemented as well as provide an update on the additional work developing the in progress model.

Objectives:

1. Discuss the factors that led to the development of the a model for levels of practice.
2. Describe the various levels in the model in relation to education and practice.
3. List some of the challenges associated with implementing the model.

#8 Anti-Nuclear Antibody (ANA) Screening

Basic - 1.0 C.E.U.

Sponsored by the Mayo Clinic

David Murray, MD PhD
Pathology Resident , Mayo Clinic

Currently, there are 3 methods used to screen the majority of the sera for ANA. The methods are 1) indirect immunofluorescent assay (IFA), 2) enzyme-linked immunosorbent assay (ELISA) and 3) fluorescent multiplex immunoassay (MIA). The current debate centers on the adequacy of the noncellular assays (ELISA and MIA) to replace IFA for ANA screening. This debate, in part, has intensified over results from the College of American Pathologists

Monday, May 24th

(CAP) proficiency testing (PT) surveys. Recent PT surveys have highlighted differences between the methods. The purpose of this session is to give the attendee an appreciation of current issues surrounding ANA screening. To accomplish this we will review the benefits and limitations of current analytical methods, and examine published comparison studies and proficiency testing results for the major ANA screening methods.

Objectives:

1. Understand the basic principles of indirect immunofluorescent assay (IFA); enzyme-linked immunosorbent assay (ELISA); and multiplex fluorescent immunoassay (MIA) technologies for antinuclear antibody (ANA) testing.
2. Recognize the limitations and benefits of the various methodologies currently used for ANA screening.
3. Appreciate how results from the ANA screening assays affect clinical decision making and treatment of patients.

11:45 AM– 1:30 PM

Lunch, Exhibits, and Dessert

*ASCP Luncheon and Business Meeting
AACC Luncheon and Business Meeting*

"Where the calculator on the ENIAC is equipped with 18,000 vacuum tubes and weighs 30 tons, computers in the future may have only 1,000 vacuum tubes and perhaps weigh 1.5 tons." Anonymous, Popular Mechanics, 1949

Monday, May 24th
1:45 PM – 2:45 PM

**#9 Plasma Exchange Therapy for
Thrombotic Thrombocytopenic
Purpura**

Intermediate - 1.0 C.E.U.

Nancy Van Buren, M.D.
Pathologist/Transfusion Services Medical Director
Central Regional Pathology Laboratory, HealthEast Care
System

This presentation will provide an overview of the etiology and pathogenesis of thrombotic thrombocytopenic purpura (TTP). Indications for therapeutic plasma exchange will be discussed, including initial management of disease and relapses. Laboratory testing for monitoring the effectiveness of treatment will be discussed, as well as the role of replacement fluids, and other technical aspects related to plasma exchange therapy.

Objectives:

1. Describe the characteristic clinical manifestations of TTP.
2. Summarize the treatment approach for the management of TTP.
3. Describe the rationale for the use of FFP or cryoprecipitate-poor plasma as the replacement fluid.
4. Describe which laboratory tests are commonly used to monitor the disease and response to plasma exchange.

*"Disconnecting from change does not recapture
the past. It loses the future"*
Kathleen Norris

Monday, May 24th

#10 What Does Proficiency Testing Really Test?

Intermediate - 1.0 C.E.U.

Dr. Anthony Killeen, Director of Clinical Laboratories
University of Minnesota Medical Center, Fairview,
Minneapolis, MN

This program will review the state of the art of proficiency testing and describe the role that PT plays in laboratory operations, its limitations, and future trends. The program will ask what can we learn about laboratory quality from PT and how can we use PT to improve quality.

Objectives:

1. Describe the current state of PT in the U.S. and future trends.
2. What can we learn about laboratory quality from PT?
3. What are the limitations of PT and how do we go beyond these?

#11 A transition to full laboratory automation

Basic - 1.0 C.E.U.

Sponsored by Mayo Clinic

Christina Marver MT (ASCP), Laboratory Supervisor
Mayo Clinic

This session will cover the planning that was utilized to implement a full lab automation project. This will include developing a thorough plan to start the automation process, defining a team to work on the project, developing a system to evaluate, select and implement the “best fit” system, setting goals and objectives for an automation project, and the progress of an automation implementation to-date with lessons learned.

Monday, May 24th

Objectives:

1. Identify the key issues to consider when beginning to plan automation.
2. Define lab specific goals and objectives of an automation project.
3. Discuss opportunities for improvement using full automation.

#12 Coagulation 101: Back to the basics... a Refresher and Update

Basic - 1.0 C.E.U.

Sponsored by Diagnostica Stago, Inc.

Karen Levisen MT(ASCP)SH

Technical Support Specialist, Diagnostica Stago, Inc.

The laboratory of today brings a need for the bench technologist to be an expert in many disciplines. Hemostasis is a very complex subject, involving many different factors and inhibitors. Without the basics, it can be difficult to understand what might be affecting results obtained on samples presented to the laboratory for analysis. A review of the basic principles of hemostasis will be included in the discussion, along with case studies to bring current challenges to a greater level of understanding.

Objectives:

1. Briefly explain the classic coagulation pathway and where the factors fit into this pathway.
2. Understand the important pre-analytical variables that can affect coagulation testing.
3. Discuss what test results would be expected in a particular factor or inhibitor disorder or deficiency.
4. Relate the clinical significance of common hemostatic disorders.

"The greatest danger to our future is apathy."

Jane Goodall

Monday, May 24th
3:00 PM – 4:00 PM

**#13 Comparative Genomic Hybridization
Becomes a Frontline Tool for the
Detection of Chromosome
Abnormalities**

Intermediate - 1.0 C.E.U.

Betsy Hirsch, PhD, Director of Cytogenetics
University of Minnesota, Fairview and Dept. of Laboratory
Medicine and Pathology, University of Minnesota Medical
School

Over the past decade, the field of cytogenetics, aimed at the detection of chromosomal abnormalities responsible for abnormal clinical findings, has changed dramatically due to advances in technology and to the knowledge gained from the sequencing of the human genome. The most current technique to have entered the clinical cytogenetics arena is microarray analysis. This session will present a basic description of array-based comparative genomic hybridization technology, and its application in the clinical laboratory.

1. Describe the basic goal of an array-based comparative genomic hybridization analysis
2. Summarize the advantages of a-CGH over conventional chromosome analysis
3. Identify a limitation of a-CGH compared to conventional chromosome analysis
4. Describe one of the recent significant findings from the clinical application of a-CGH

**#14 Living a Balanced Life and Managing
Stress**

Basic - 1.0 C.E.U.

Monday, May 24th

Tania McVean, Community & Hospital Relations
Coordinator, Memorial Blood Centers

Living a balanced life and managing stress is a major challenge in today's busy world. It is very easy to throw your hands up in despair. Despair not. This session will talk about simple ways to alleviate stress in your day to day life and how exercise can help. Small changes can make a big difference!

Objectives:

1. Assess and reduce daily stress.
2. Describe how to start a basic exercise program.
3. Describe the affect of stress on both body and mind and how to alleviate the effects.

#15 ASCLS Annual Meeting

Bobbi Kochevar, President ASCLS-MN
Basic - 1.0 C.E.U.

This is our annual membership meeting where new leaders are voted in, the next fiscal year's budget is approved, updates on critical lab issues are presented from the state, regional and national perspective and members are recognized for accomplishments throughout the year. All ASCLS members and those interested in joining ASCLS are invited to attend.

Objectives:

1. Explain the financial viability of their professional society.
2. Understand the challenges of the MN licensure bill and the necessary steps moving forward.
3. Describe the structure of ASCLS and how the state of MN ties into the National structure.
4. Through committee reports, understand current legislative challenges and how these decisions impact the laboratory profession.

Monday, May 24th

#LF 1 Lab Futures: Point-of-Care testing

A Chance to Learn from Vendors

Basic to Intermediate 1.0 C.E.U.

This training workshop provides an opportunity to compare and evaluate Point-of-Care instruments and supplies for use in a clinical or at home setting. This information will be presented in a small group environment giving you an opportunity to have a meaningful dialog with individual vendors.

4:00 PM - 5:30 PM

EXHIBITS and SOCIAL HOUR

*Come see the vendors, enjoy
complimentary hors d'oeuvres, and
socialize with your laboratory
colleagues*

Cash bar will be available

*"To excel the past we must not allow ourselves to
lose contact with it; on the contrary, we must
feel it under our feet because we raised ourselves
up on it."*

José Ortega y Gasset

Tuesday, May 25th, 2010

Tuesday, May 25th

7:00 AM – 8:00 AM

Registration and Continental Breakfast
Educators Breakfast

8:00 AM – 9:30 AM

Keynote Address

*2010 Health Policy for Lab
Professionals:*

*The Effect of Reform, Shortages and
Closures*

Intermediate – 1.0 CEU

Presented by:

**Jeff Jacobs, MA, Vice President
Public Policy and Government
Relations
American Society for Clinical
Pathology**



Sponsored by



American Society for
Clinical Pathology

Tuesday, May 25th, 2010

Focus will be given to the future of laboratory medicine given the tremendous number of policy proposals that surfaced during the 2009-2010 health care reform debate. Legislation or not, our field will experience tremendous changes in the coming years. The field will need to be prepared for the ongoing policy debates that are raging in Washington, St Paul, and other centers of political power.

Objectives:

1. Describe public policy issues that will impact laboratory practice and management.
2. Discuss the impact of the laboratory professional shortage.
3. Describe how Minnesota's Department of Labor program to train laboratorians is unique.
4. Summarize the prospects of health reform and the future of the field of lab medicine.

9:30 AM – 10:30 AM

#17 Advances in PSA testing

Basic - 1.0 C.E.U.

Sponsored by



Chris White, PhD,

Scientific Affairs Manager, Beckman Coulter, Inc.

Prostate Specific Antigen (PSA) testing is an effective way to better identify patients who may be at risk for prostate cancer. While elevated PSA results lead physicians and patients to recommend biopsy, roughly 75% of all prostate biopsies are negative. We will discuss current biochemical PSA testing recommendations and new discoveries showing promise for better prostate cancer detection.

Objectives:

1. Describe Prostate Disease.
2. Define Prostate Cancer.
3. Identify tests used for detecting prostate cancer and for monitoring therapy.

Tuesday, May 25th, 2010

#18 Osteoporosis and the role of Bone Metabolism Biomarkers

Basic - 1.0 C.E.U.

Sponsored by



Jessica M. Mattke, MPH, MT (ASCP)
Sr. Specialist Strategic Marketing
Beckman Coulter, Inc.

Bone Metabolism is a continuous process in humans of all ages. As we age, we need to become more aware of the process and how we can monitor and impact bone loss. We will discuss what bone metabolism is, what osteoporosis is and discuss some of the biochemical tests used for detecting osteoporosis and monitoring therapy.

Objectives:

1. Describe bone metabolism.
2. Define Osteoporosis.
3. Identify tests used for detecting osteoporosis and for monitoring therapy.

#19 You Expect Me to Do Real Work AND Teach?

Intermediate - 1.0 C.E.U.

Sponsored by



Patricia J. Ellinger, MSED, MLS(ASCP)SBB
Program Director, St. Cloud State University

Pat will discuss efficient and effective techniques for teaching at the bench while accomplishing a normal workload. Learn how to challenge students to identify their “Muddy Moments” and to learn from them. Discover how to convert “real work” into useful learning

Tuesday, May 25th, 2010

tools as case studies, and discuss advantages of being a clinical site. Try to convince Pat that your lab doesn't need to or can afford not to teach students!

Objectives:

1. Define "Muddy Moments" and describe how to use them.
2. Increase confidence and speed of instructors and students.
3. Convert "real work" into case studies.
4. List 2 advantages of being a clinical site.

#20 Immunology Refresher/Update

Basic - 1.0 C.E.U.

Sponsored by



Robbi Montgomery, MLS, MLS(ASCP)^{CM} SI

Director of Education, Clinical Laboratories, Hennepin County Medical Center

This session will provide a brief look at applying our knowledge of immunology to today's increasingly automated clinical laboratory. A basic refresher on the immunologic principles which are required for trouble-shooting and problem solving will be included. Clinical immunology methods such as flow cytometry and autoimmune testing are highlighted.

Objectives:

1. State why it is necessary to know if a method is immunology-based (antigen-antibody) when trouble-shooting assay problems.
2. Describe at least two types of interference that can occur in antigen-antibody reactions.
3. Discuss why automation can sometimes have a negative influence on certain assays.
4. State the utility of flow cytometry in clinical laboratories.

Tuesday, May 25th, 2010
10:45 AM – 11:45 AM

**#21 Transplant Immunology: HLA Testing
in Solid Organ and Stem Cell
Transplantation**

Intermediate - 1.0 C.E.U.

**Sponsored by University of Minnesota Medical Center,
Fairview**

Harriet J. Noreen, Technical Supervisor
University of Minnesota Medical Center, Fairview

This session will discuss the basics of the HLA (human leukocyte antigens) system and the relationship of HLA testing to solid organ and stem cell transplantation.

Objectives:

1. Discuss basic HLA structure, function, genetics and nomenclature.
2. Summarize HLA assays used in stem cell and organ transplantation.
3. Discuss the organ allocation process.

**#22 Beyond the Routine CBC – The
Empowered Lab**

Intermediate - 1.0 C.E.U.

Sponsored by Sysmex America, Inc.

Barbara J Connell MS, MT(ASCP)SH, Sr. Manager
Scientific Marketing, Sysmex America, Inc.

This program will introduce its participants to the advanced clinical parameters that are available on a routine hematology analyzer. Many of these parameters can be used to evaluate various aspects of hematopoiesis. The technology used to determine these advanced clinical parameters, as well as some of the clinical applications will

Tuesday, May 25th, 2010

be presented. Parameters to be discussed include: Immature Reticulocyte Fraction, Immature Platelet Fraction and Reticulocyte Hemoglobin.

Objectives:

1. Explain the technology and the operational benefits of the advanced clinical parameters.
2. Describe at least 2 clinical applications for each advanced clinical parameter discussed.
3. Describe steps needed to implement these advanced clinical parameters in your lab.

"Remembering the past gives power to the present"
Anonymous

#23 Making the Leap to Online Learning

Basic - 1.0 C.E.U.

Sheri Steinke

Director of Online Learning and Adjunct Faculty
North Hennepin Community College

Technology is rapidly advancing and keeping up with it or applying it to your situation can be difficult when you are uncertain about what is available, how easy it is to learn, and how to apply it to your situation, right away. In this session, we will discuss user-friendly technology tools to be collaborative, share information, and deliver content training.

Objectives:

1. Identify technology and collaboration needs in your organization.
2. Understand the application of these collaborative technology tools to ordinary situations.
3. Discuss the implications of applying collaborative tools in secure environments.
4. Apply several collaborative technology tools to a learning need.

Tuesday, May 25th, 2010

#24 The Changing World of Certification

Intermediate - 1.0 C.E.U

Kathy Hansen, MLS(ASCP)^{CM}
Consulting Laboratory Director,
Fairview Health Services

The National Credentialing Agency (NCA) and the ASCP Board of Registry (BOR) merged on 10/23/09 to form the ASCP Board of Certification (BOC). We will review the status of laboratorians formerly certified by the parent agencies, the use of the new title MLS(ASCP), and requirements for recertification.

Objectives:

1. Describe the certification status of former NCA and ASCP certified individuals.
2. List reasons for participation in recertification.
3. Distinguish between certification and membership organizations.

#LF-2 Lab Futures: Chemistry Testing

A Chance to Learn from Vendors
Basic to Intermediate - 1.0 C.E.U.

This training workshop provides an opportunity to compare and evaluate supplies, reagents, and equipment used in a clinical chemistry laboratory. This information will be presented in a small group environment giving you an opportunity to have a meaningful dialog with individual vendors.

*"I look to the future because that's where I'm
going to live the rest of my life."
George Burns*

Tuesday, May 25th, 2010
11:45 AM– 1:30 PM
Lunch and Exhibits

AMT Luncheon and Business Meeting

*CLMA Luncheon and Business Meeting followed by
Hot Topics discussion moderated by Tami Stanger*

Intermediate - 2.0 C.E.U.

Participants will bring hot topics or questions in the laboratory industry to the forum to be discussed amongst peers in addition to the presenter having the following topics prepared for discussion; the student intern site bottleneck, benchmarking tools, inspection agency comparison and comments from recent inspections, corporate benefits of CLMA membership for chapters and members, techniques to bring together generations in the workforce; ie. Huddles, communications, etc.

Objectives:

1. Discuss what the Hot Topics in the laboratory industry are.
2. Have an understanding of the need, the benefits, and the requirements for student intern sites.
3. Have tools to take back and use for benchmarking in the medical laboratory.

1:45 PM – 2:45 PM

**#25 Hepatitis A, B & C – Making Sense of
Alphabet Soup**

Intermediate 1.0 - C.E.U.

Paige O'Keefe, Lead Medical Technologist of Infectious
Diseases & Serology
HealthPartners Central Laboratory

Tuesday, May 25th, 2010

Attendees will learn the appropriateness of ordering Hepatitis lab tests, such as: antigen, antibody or nucleic acid testing as well as to understand some differences between the testing methods. Attendees will also learn how Hepatitis Testing Algorithms / Cascades can be useful, how the laboratory can play an integral role in the development of these algorithms as well as assisting providers with education surrounding the algorithms.

Objectives:

1. To understand the differences between laboratory methods for the various Hepatitis tests.
2. To understand the appropriateness of Antigen, Antibody and / or Nucleic Acid testing
3. To understand how Hepatitis Testing Algorithms / Cascades can be useful.
4. To learn how the laboratory can play an integral part in developing algorithms and educating providers.

#26 Urinalysis Review: From Optimizing the Microscope to Identifying Cells

Intermediate - 2.0 C.E.U.

Nancy Brunzel, MS, CLS(NCA)
Assistant Professor, University of Minnesota

This presentation will begin with a review of microscope illumination and the steps required to optimize the performance of this indispensable laboratory tool, including the adjustments required for wet preps versus smears. Distinguishing characteristics of challenging microscopic elements and tips to properly identify them will be discussed as well as the clinical significance of microscopic hematuria. Causes for discrepancies between the chemical and microscopic exams and the value of performing a microscopic exam on all specimens will be shared.

Objectives:

1. Describe how to properly adjust a microscope's illumination system to achieve optimum viewing performance.

Tuesday, May 25th, 2010

2. Describe and use distinguishing characteristics of urine sediment components to properly identify them using brightfield microscopy.
3. Discuss reflex testing versus 100% microscopy and the resulting differences.
4. Discuss the clinical significance of microscopic hematuria.

#27 Boot Camp – Basic Training for Establishing a Training Program

Intermediate - 1.0 C.E.U.

Jeanne S. Eull, Education Specialist II
Mayo Clinic

This “Basic Training” program will provide information and guidance on how to establish a training program in your lab. The session will include a review of regulatory requirements, performing a needs assessment, forms used for creating and documenting training, and ideas for evaluating your training program.

Objectives:

1. List the regulatory requirements for a training program.
2. Describe the components of good training documents.
3. Discuss ways to assess the quality of a training program.

#28 Clinical Microbiology 101: A Review for the Generalist

Basic - 1.0 C.E.U.

Sponsored by MIMA



Edward Steffen Morrow Jr., MT (ASCP)
Children’s Hospitals and Clinics of Minnesota

Tuesday, May 25th, 2010

A general review will include: the role of the Gram stain on patient care, the more frequently encountered microbes in the clinical laboratory, and the principles of good specimen collection, processing, and initial plating. The fundamental basics of culture interpretation for routine urine, throat, and stool cultures will be included. Examples of some common problems and solutions related to specimen management will also be shared.

Objectives:

1. Discuss the principles of specimen management and collection.
2. List the characteristics of the more common clinical microbes.
3. Summarize the basic guidelines for routine culture interpretation.
4. Discuss how to pragmatically approach specimen management problems.

3:00 PM – 4:00 PM

#29 You've Come a Long Way Babies- Newborn Screening in Minnesota Intermediate - 1.0 C.E.U.

Beth-Ann Bloom, MS, CGC, Genetic Counselor
Minnesota Department of Health, Newborn Screening
Program

Newborn Screening began in Minnesota in the 1960's with testing for PKU. Now, screening for over 50 disorders is available to every baby born in our state. With the support and cooperation of laboratorians in hospital and specialty labs statewide, the opportunity for pre-symptomatic testing and treatment for even more of the serious and fatal conditions of infancy can be part of the future for Minnesota babies.

Tuesday, May 25th, 2010

Objectives:

1. Name 3 disorders on the Minnesota Newborn Screening panel.
2. Describe when newborn screening specimens should be collected.
3. Discuss why newborn screening should NOT be called “The PKU test.”

**#30 Mapping and Managing the Customer
(Donor) Phlebotomy Experience**

Intermediate - 1.0 C.E.U.

Sponsored by Memorial Blood Centers

Kristine Belanger, MT (ASCP)

Sr. Director of Collections and Production Planning,
Memorial Blood Centers

Using the blood donor as an example of the phlebotomy experience, this session will highlight the importance and methods for determining requirements for customers, provide an overview of how the customer experience can be mapped into a technical process, outline the elements of a training program aimed at meeting and exceeding the expectations of customers and review supporting elements of a customer-focused culture including measurement, performance management and recognition.

Objectives:

1. Describe the importance and identification of customer requirements
2. Describe a method to incorporate customer requirements into a technical process.
3. Describe elements of a training program aimed at meeting and exceeding customer requirements.
4. Summarize the importance and elements of i) a good measurement and ii) performance management system in order to meet and exceed customer requirements.

Tuesday, May 25th, 2010

#31 Osteopathic Medicine and Women's Health

Intermediate - 1.0 C.E.U.

Dr. Karysse Trandem, DO, Resident Physician
University of Minnesota, Department of Obstetrics,
Gynecology, and Women's Health

Osteopathic Medicine is the holistic study of medicine as it relates to the mind, body, and spirit. Osteopathic Doctors undergo the same training as traditional medical doctors with additional coursework in osteopathic philosophy and manipulation of the body. This session will explain and demonstrate the approach of the osteopathic physician and will also touch on techniques to assist with optimizing specific women's health issues.

Objectives:

1. Define Osteopathic Medicine and Manipulation.
2. Describe Osteopathic Manipulation Treatments.
3. Discuss the philosophy of Osteopathic Medicine.
4. Explain an Osteopathic approach to women's health.

#LF-3 Lab Futures: Computers/Software

A Chance to Learn from Vendors
Basic to Intermediate 1.0 C.E.U.

This training workshop provides an opportunity to compare and evaluate computer software that is used in the laboratory setting. This information will be presented in a small group environment, giving you an opportunity to have a meaningful dialog with individual vendors. This information will be valuable whether you are already using an LIS system or are shopping for a software program that will enhance your laboratory.

Tuesday, May 25th, 2010

4:00 PM – 5:30 PM

Exhibits, Silent Auction, and Social Hour

- 4:45 PM Silent Auction ENDS
- 5:00 PM Auction Winners Announced



**Light Snacks served in
Exhibit Hall**

Tuesday, May 25th, 2010
2010 Clinical Laboratory
Collaborative Social Event



Minnesota History Center
345 Kellogg Boulevard West, St Paul, MN

May 25th, 2010
5-8:30 pm.

Social Hour with Cash Bar 5-6 pm.
Lovely Sit-down Dinner with dessert 6-7 pm.

Tour of Minnesota History Center 6-8:30 pm.
Transportation provided to and from Crowne Plaza Hotel

Cost \$20

Sponsored by
MEDSTAT SYSTEMS, INC.
“The **Vital Link** between Patient and Provider”
www.medstatsystems.com
and
the Clinical Lab Collaborative

Wednesday, May 26th

Wednesday, May 6th

7:00 AM – 8:00 AM

Registration and Continental Breakfast

8:00 AM – 9:00 AM

#32 The Potential Role of the Laboratory in Assessing Platelet Inhibitors

Intermediate - 1.0 C.E.U.

Elizabeth Jaben, MD
Resident Physician, Anatomic and Clinical Pathology
Mayo Clinic

Requests from clinicians regarding testing to assess for resistance to drugs such as aspirin are becoming more frequent due to the consequences of inadequate anticoagulation. In this session, there will be a basic review of platelet function followed by a discussion of platelet inhibitors. We will then look at different laboratory tests which can be used to assess platelet response to anti-platelet therapy and review literature on each method.

Objectives:

1. Understand the basic function of platelets.
2. Describe the mechanism for common anti-platelet therapies.
3. Discuss different laboratory assessments of resistance to anti-platelet drugs.
4. Summarize the benefits and limitations to each method.

#33 Data Capture and Analysis

Basic - 1.0 C.E.U.

Sponsored by Mayo Clinic

Julie Doppler, Systems Engineer
Mayo Clinic

Wednesday, May 26th, 2010

This course will introduce the attendees to the basic concepts of data collection and analysis. We will be discussing the importance of collecting the useful data as well as having an appropriate plan for the information. We will cover why understanding data collection is vital to measuring objectives. We will also discuss how to use and analyze information/data to be able to respond to what it is showing. The goal is to allow the user to know how to gather the information, choose an appropriate chart and plan the use of the information to act on an objective. After discussing the data collection plan we will review the rules to understanding variation, common cause and special cause. This course will also share some examples of how to put these theories into practice in the laboratory setting.

Objectives:

1. Tie an objective to a data analysis plan.
2. Create a data analysis plan.
3. Identify the appropriate chart for the data analysis plan.
4. Recognize basic SPC charting.
5. Identify and react to abnormal variation in data/chart.

#34 Change Management with Positive Reinforcement

Intermediate - 1.0 C.E.U

Mary Foss, Laboratory Operations Manager
Division of Transfusion Medicine and Performance
Management Advisor
Mayo Clinic, Department of Laboratory Medicine and
Pathology

This presentation will describe the change process of “endings, transitions, and beginnings” as well as a process called Performance Management that uses the scientific study of human performance (Applied Behavior Analysis). The value of using Performance Management as a tool to help with Change Management will be discussed and several examples will be shared.

Wednesday, May 26th, 2010

Objectives:

1. Describe the change process.
2. Discuss the ABC model of Performance Management.
3. Describe the value of using Performance Management for Change Management.

#35 News and Reviews in Hematology

Basic - 1.0 C.E.U.

Christine Hinz, MLS, Lead Hematology Technologist
Abbott Northwestern Hospital

This program will provide a review of hematology cell types and interesting case studies seen at the Abbott Northwestern laboratory. New and upcoming parameters that can aid in oncology and anemia diagnosis will also be discussed.

Objectives:

1. Describe cell types seen in the hematology laboratory.
2. Correlate cell types with case studies.
3. Identify and understand new technology in hematology.

9:15 AM – 10:15 AM

#36 Preeclampsia: New Concepts, New Tools

Intermediate 1.0 - C.E.U.

Sponsored by



Linda C Rogers, PhD, Scientific Manager
Beckman Coulter, Inc.

Preeclampsia, a potentially devastating complication of pregnancy, has been known for centuries. Preeclampsia affects 5 to 8 percent of all pregnancies and is associated with morbidity and mortality of both mothers and babies. This session provides an overview of angiogenesis and its role in the pathogenesis of preeclampsia. One of the dilemmas in diagnosing preeclampsia is that the associated

Wednesday, May 26th, 2010

symptoms are non-specific and can be seen in normal pregnancies. The syndrome of preeclampsia as well as the diagnostic issues facing physicians will be reviewed. Two biomarkers, placental growth factor (PIGF) and soluble vascular endothelial growth factor receptor (sVEGF R1) will be described emphasizing their potential utilization in the diagnosis and management of preeclampsia during pregnancy. Supportive data will be shown from recent studies. As these biomarkers become readily available, physicians use these tests to guide the care of their patients, filling a significant unmet need in prenatal care.

Objectives:

1. Define “angiogenesis”.
2. List several biomarkers with potential utility in the management of preeclampsia.
3. Summarize the role of angiogenesis in the pathogenesis of preeclampsia.
4. Describe a scenario in which the utilization of the angiogenic biomarkers could influence prenatal care.

#37 The Role of the Clinical Microbiology Laboratory in Changing Health Care Systems

Basic - 1.0 C.E.U.

Nicole Zitterkopf Khoury, PhD., D(ABMM), MT(ASCP),
Assistant Professor, University of Minnesota
Center for Allied Health Programs, Clinical Laboratory
Science

The role of the clinical microbiology laboratory is not only to accommodate change in the healthcare system, but to drive it. This presentation will highlight the role of the laboratory in clinical data reporting and patient management. Examples of patient safety and patient care improvements directly involving the microbiology laboratory will be discussed as will our role as clinical laboratory scientists to drive innovation in laboratory medicine.

Wednesday, May 26th, 2010

Objectives:

1. Recommend a practice or procedure that may be implemented into your laboratory to improve quality of care.
2. Compare the turn-around time for culture and molecular assays with respect to hospital-acquired infections.
3. Summarize the integrated role of the microbiology laboratory with respect to judicious use of antimicrobials.
4. Describe one example of how the microbiology laboratory drives innovation in laboratory medicine.

#38 Personnel Licensure: The 2010 Leg of the Journey

Intermediate - 1.0 C.E.U.

Rick Panning, MBA, MLS(ASCP), Vice President,
Laboratory Services Allina Hospitals and Clinics
Co-chair, Minnesota Laboratory Licensure Coalition

After successful passage in three Senate committees of the Minnesota legislature, the Medical Laboratory Licensure bill began its journey in the House of Representatives in February 2010. By the time the state CLC meeting occurs, we will know if the bill made progress towards passage or failed to pass the necessary committees in the House. This session will chronicle the activities of the licensure coalition since the spring of 2009, including development of a fiscal note to understand the financial costs of licensure, work to have the bill reviewed by the Council of Health Boards, work with CAP and the Minnesota pathologists to make changes in the bill and advocacy efforts related to 2010 passage of the bill. A summary of opponent arguments will also be discussed.

Objectives:

1. Describe the successful passage by three Minnesota Senate committees in 2009.
2. Describe the purpose of the Minnesota Council of Health Boards review of licensure bills.
3. List three arguments against licensure by opponents of the bill.
4. Summarize what happened to the licensure bill in the 2010 legislative session.

Wednesday, May 26th, 2010

**#39 Pediatric Phlebotomy:
Success from Start to Finish**

Basic - 1.0 C.E.U.

Erin Peper
Assistant Supervisor Pediatric Lab Services
Mayo Clinic

This session will focus on the importance of training for pediatric phlebotomy for both inpatient and outpatient settings. Communication with the patient, parents, physicians, and co-workers will be discussed. In addition, using the H.E.A.T. technique for a successful venipuncture, painless approaches, venipuncture versus capillary collections, and different comfort positions will be reviewed.

Objectives:

1. Identify different training methods for pediatric phlebotomy in outpatient and inpatient areas.
2. Describe how to use H.E.A.T. for a successful pediatric venipuncture.
3. Recognize the importance of communication in pediatric phlebotomy.

**#LF-4 Lab Futures: Hematology and
Coagulation Testing**

A Chance to Learn from Vendors
Basic to Intermediate 1.0 C.E.U.

This training workshop provides an opportunity to compare and evaluate supplies, reagents, and equipment used in a clinical hematology/coag laboratory. This information will be presented in a small group environment thus giving you an opportunity to have a meaningful dialog with individual vendors.

Wednesday, May 26th, 2010

10:15 AM – 11:30 AM

Exhibits

Last chance!

11:30 AM – 1:00 PM

Lunch and Final Keynote Address

*Remembering our History:
Legacies that Shape Our Future*

Intermediate – 1.0 C.E.U.

Presented by

Karen R. Karni, Ph.D., CLS (NCA)

Professor Emeritus, University of Minnesota

ASCLS was founded in 1933, but the Twin Cities Society of Clinical Laboratory Technicians was initiated in 1924.

Minnesota laboratorians have always been ahead of their time.

Overall, history (from the 1920s to current years) will be discussed, with the emphasis on Minnesota's significant part in the professionalization of laboratory science.

Objectives:

1. Describe four historical and ongoing issues in laboratory science.
2. State three major accomplishments by Minnesotans in the advancement of the profession.
3. Identify and articulate the importance of licensure, certification, accreditation, education, publications, and government/community involvement for a profession.
4. Actively demonstrate pride in this profession within one's employing institution and larger community.

Wednesday, May 26th, 2010

1:15 PM – 2:15 PM

#40 Updates in the Diagnosis and Management of Diabetes: What is the Role of Hemoglobin A1c and the Estimated Average Glucose (eAG)?

Intermediate - 1.0 C.E.U.

Amy K. Saenger, Ph.D.

Director, Central Clinical Laboratory, Mayo Clinic

Diabetes is associated with significant morbidity and mortality and its prevalence is rapidly increasing. The 2010 American Diabetes Association Guidelines now recommend hemoglobin A1c (HbA1c) as the preferred marker for the diagnosis of diabetes, replacing the fasting plasma glucose and oral glucose tolerance test (Diabetes Care, Vol 33, S1, 2010). This session will provide background information on diabetes, glucose testing and controversies, hemoglobin A1c (HbA1c), the estimated average glucose (eAG), and current standardization efforts surrounding measurement of HbA1c. Treatment and management of diabetes based on HbA1c targets, as well as correlations (both synergistic and discrepant) between HbA1c and the estimated average glucose (eAG) will be presented.

Objectives:

1. Describe the current guidelines and recommendations for the diagnosis of various types of diabetes.
2. Compare and contrast the various methodologies available for measurement of HbA1c.
3. Evaluate the relationship between estimated average glucose and HbA1c, and the controversies that surround reporting these analytes.

Wednesday, May 26th, 2010

#41 H1N1 Pandemic Influenza Experience at Children's Hospitals and Clinics of MN

Intermediate - -1.0 C.E.U.

Julie LeBlanc, MPH and Helen Stefan, MT(ASCP) SV
Children's Hospitals and Clinics of MN

This session will provide an overview of Children's Hospitals and Clinics of MN experience with managing patients and circumstances due to H1N1. Content will include Children's response plan, managing unprecedented patient volumes, the epidemiology of H1N1 2009 pandemic influenza, transmission of influenza, and vaccine distribution. Specific emphasis on H1N1 laboratory testing will be provided including CDC diagnostic testing guidance, testing eligibility criteria throughout the pandemic and the Children's laboratory impact and response.

Objectives:

1. Discuss the epidemiology of H1N1 2009 pandemic influenza.
2. Describe the testing algorithm used for H1N1.
3. Summarize Children's experience with managing patients and circumstances due to H1N1.

#42 Changes in Cytogenetics: Old and New

Basic - 1.0 C.E.U.

Leanna Erickson, Retired
University of Minnesota
Association of Genetic Technologists

Discuss early changes in technology, staffing, training, certification and demographics for Cytogenetic Labs.

Describe a "typical cytogenetics lab" in the 1970's, 1980's, 1990's and 2010. What will the future Cytogenetic Labs and lab personnel look like?

Wednesday, May 26th, 2010

Objectives:

1. Name some basic technology terms used in cytogenetics.
2. Summarize some of the changes in cytogenetics.
3. Describe the role of a cytogenetic technologist.
4. Correlate some technology changes with society changes and medical breakthroughs.

#43 Blood Bank Refresher/Update

Intermediate - 1.0 C.E.U.

Sponsored by



American Society for
Clinical Pathology

Patricia J. Ellinger, MSED, MLS(ASCP)SBB
Program Director, St. Cloud State University

Pat will present an update on blood bank topics especially for those seeking to complete the Certification Maintenance Program and for those wondering what has been going on behind those BB doors since you left. Topics will include:

Antibody identification methods - what's in, what's out; ISBT – 128 Labels; TRALI; RBC substitutes - where are they?

Objectives:

1. Describe the basic steps in deciphering an antibody panel.
2. List 2 advantages of the ISBT-128 labeling system.
3. Write out the words for TRALI.
4. State the primary challenge in producing a suitable RBC substitute.

2:30 PM – 3:30 PM

#44 A Kiss That Lasts Forever: the Epstein-Barr Virus Odyssey

Intermediate - 1.0 C.E.U.

Hank Balfour, MD

Professor, University of Minnesota Medical School

Wednesday, May 26th, 2010

This talk describes the discoveries of infectious mononucleosis and Epstein-Barr virus and how that history exemplifies the complexity of EBV's relationship with its host. The clinical features of EBV infections will be discussed and correlated with the laboratory tests of choice to diagnose and monitor their progression. Recent research advances in the epidemiology, immunology, prevention and treatment of EBV diseases will be assessed.

Objectives:

1. Discuss the history of the discovery of mono and EBV and understand how that history exemplifies the complexity of EBV's relationship with the host.
2. Correlate the clinical and laboratory findings in EBV infections.
3. Assess advances in epidemiology, immunology, prevention and treatment of EBV infections.

#45 Healthcare and Laboratory Medicine in China

Basic - 1.0 C.E.U.

Jillene Collins, Technical Sales Manager, The Binding Site

This will be a presentation on experiences from the Laboratory delegation that visited China. The presentation will include descriptions of experiences and information from both large urban laboratory facilities and small local community hospitals. This will include a recap of the delegation's exchange of information with the labs and will also touch on the culture and living conditions as well as the general health care and laboratory systems in China.

Objectives:

1. Describe the QA and QC systems that are being utilized in laboratories across China.
2. Describe some of the unique challenges that laboratories in China are facing.
3. Summarize the general expertise levels and technology levels in these laboratories.
4. Summarize the basics of the communities and living situations of the places the delegation visited.

Wednesday, May 26th, 2010

#46 Positioning your Organization for Success

Intermediate - 1.0 C.E.U.

Sponsored by Memorial Blood Centers

Rovena Claxton, M.A., SPHR

Vice President of Organization Development

Memorial Blood Centers

In today's tough economy, many organizations, their leadership, and their workforce not only survive, but thrive. What is the difference between those that do and those that don't? How do we as professionals in our respective organizations find both success and satisfaction in times of change, "downsizing," and "Lean"?

Objectives:

1. Identify critical success factors for organizations in times of change.
2. Discuss the key attributes of "leadership" in transition.
3. Develop "measures" of personal effectiveness.
4. Set and achieve developmental goals.

#47 Improving the Quality of Service through the Critical Incident Approach

Intermediate - 1.0 C.E.U.

Sponsored by Memorial Blood Centers

Mark A. Janzen, PhD

Director of Laboratory Medicine

Memorial Blood Centers

In today's competitive marketplace it is critical that organizations are able to produce high-quality products and/or high-quality services. Organizations that know their customer's requirements will improve their ability to make better business decisions – and to determine if they are meeting their customer's requirements. Methods to measure the customer's perception of quality must be properly developed to ensure that they accurately represent the customer's opinions in order to make better decisions to better serve the customer.

Wednesday, May 26th, 2010

Objectives:

1. Discuss the importance of understanding your customer's requirements.
2. Describe methods to determine customer requirements.
3. Define the critical incident approach to determining customer requirements.
4. Describe a method to turn customer requirements into a survey to measure satisfaction.

*"We can not always build the future for
our youth, but we can build our youth
for the future"*
Franklin D. Roosevelt

Co-Chairs:
Valerie Arends Carrie Bowler Jillene Collins

Sub-Committees

Audiovisual	Ad Hoc
Carrie Bowler *	Barb Dietzman
Continuing Education	Carol Johannes
JoAnn Nickles *	Clara Boykin
Cindy Thompson	Edith Teft
Exhibitors	Heather Herring
Cheryl Swinehart *	John Stejskal
Brad Witten	Kaylene Landon
Cindy Savard	Mary Menden
Judy Peterson	Roxann Gavin
Moderators	Safiya Badhaso
Valerie Arends *	Registration
Pat Ellinger	Jessica Mattke *
Cindy Savard	Tom Massmann **
Karl Ness	Marya Awker
Program	Debra Westerberg
Jan Frericks *	Social
Rose Currie **	Sue Iddings *
May Jane Yue	Rachel Markwardt
Jannet Fennert	Robin Spencer
Nancy Brunzell	Brenda Scramm
Leanna Erickson	Silent Auction
Jannet Fennert	Pat Powers *
Judy Peterson	Liz Panning
Kaylene Landon	Rick Panning
Publicity	Student Activities
Renee Burke *	Amber Borowick *
Carol Lee *	Carol McCoy
Tina Bjorkstrand **	Laurie Bjerklie
Claudine Fasching	
Nicole Osterhaus	
Susan Retka	* Committee Chair
Michelle Stevens-Brioschi	** Committee Mentor